A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors

SAR and QSAR in Environmental Research

Volumn 22, Issue 1-2, 2011, Pages 171-190

  Bagga, V ^a   Silakari, O ^a   Ghorela, V S ^a   Bahia, M S ^a   Rambabu, G ^b   Sarma, J ^b  

^a PUNJABI UNIVERSITY   (India)

^b GVK BIOSCIENCES PVT LTD   (India)

Author keywords

Fischer's test; Interleukin 2 inducible t cell kinase; Pharmacophore; Tyrosine kinase; Virtual screening

Indexed keywords

AMINO ACIDS; DIAGNOSIS; ENZYMES; HYDROGEN BONDS; MOLECULES; PHARMACODYNAMICS; SEARCH ENGINES;

FISCHER TEST; INHIBITOR SCREENINGS; INTERLEUKIN-2-INDUCIBLE T-CELL KINASE; INTERLEUKIN2 (IL2); KINASE INHIBITORS; PHARMACOPHORE MODELS; PHARMACOPHORES; TEST SETS; TYROSINE KINASE; VIRTUAL SCREENING;

T-CELLS;

EID: 79952516390     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2010.510480     Document Type: Article

References (34)

1. C.I.E. Smith, T.C. Islam, P.T. Mattsson, A.J. Mohamed, B.F. Nore, and M. Vihinen, The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Txk and homologs in other species, Bioessays 23 (2001), pp. 436-446.
2. X.C. Liao and D.R. Littman, Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk, Immunity 3 (1995), pp. 757-769.
3. S.B. Kanner and J.J. Perez-Villar, Altering T-cell activation by targeting the multidomain tyrosine kinase Itk, Trends Immunol. 24 (2003), pp. 249-253.
4. G.M.T. Cheetham, Novel protein kinases and molecular mechanisms of autoinhibition, Curr. Opin. Struc. Biol. 14 (2004), pp. 700-705.
5. P.S. Ohashi, T-cell signaling and autoimmunity: Molecular mechanisms of disease, Nat. Rev. Immunol. 2 (2002), pp. 427-438.
6. T.A. Lin, K.W. McIntyre, J. Das, C. Liu, K.D. O'Day, B. Penhallow, C.Y. Hung, G.S. Whitney, D.J. Shuster, X. Yang, R. Townsend, J. Postelnek, S.H. Spergel, J. Lin, R.V. Moquin, J.A. Furch, A.V. Kamath, H. Zhang, P.H. Marathe, J.J. Perez-Villar, A. Doweyko, L. Killar, J.H. Dodd, J.C. Barrish, J. Wityak, and S.B. Kanner, Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43 (2004), pp. 11056-11062.
7. E. Schaeffer, G. Yap, C. Lewis, M. Czar, D. McVicar, A. Cheever, A. Sher, and P. Schwartzberg, Mutation of Tec family kinases alters T helper cell differentiation, Nat. Immunol. 2 (2001), pp. 1183-1188.
8. E. Schaeffer, Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity, Science 284 (1999), pp. 638-641.
9. D. Fowell, K. Shinkai, X. Liao, A. Beebe, R. Coffman, D. Littman, and R. Locksley, Impaired NFATc translocation and failure of Th2 development in Itk deficient CD4 T cells, Immunity 11 (1999), pp. 399-409.
10. C. Mueller and A. August, Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK, J. Immunol. 170 (2003), pp. 5056-5063.
11. K. Liu, S. Bunnell, C. Gurniak, and L. Berg, T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells, J. Exp. Med. 18 (1998), pp. 1721-1727.
12. A. Miller, H. Wilcox, Z. Lai, and L. Berg, Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet, Immunity 21 (2004), pp. 67-80.
13. F.M. Uckun and C. Mao, Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia, Curr. Pharm. Design 10 (2004), pp. 1083-1091.
14. S.B. Kanner and J.J. Perez-Villar, Altering T-cell activation by targeting the multidomain tyrosine kinase Itk, Trends Immunol. 24 (2003), pp. 249-253.
15. A. August, A. Fischer, S. Hao, C. Mueller, and M. Ragi, The Tec family of tyrosine kinases in T cells, amplifiers of T cell receptor signals, Int. J. Biochem. Cell B. 34 (2002), pp. 1184-1189.
16. Accelrys discovery studio 2.5. Accelrys, San Diego, CA, USA, software available at http://www.accelrys.com
17. J. Das, C. Liu, R.V. Moquin, J. Lin, J.A. Furch, S.H. Spergel, K.W. McIntyre, D.J. Shuster, K.D. O'Day, B. Penhallow, C.Y. Hung, S.B. Kanner, T.A. Lin, J.H. Dodd, J.C. Barrish, and J. Wityak, Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors, Bioorg. Med. Chem. Lett. 16 (2006), pp. 2411-2415.
18. J. Das, J.A. Furch, C. Liu, R.V. Moquin, J. Lin, S.H. Spergel, K.W. McIntyre, D.J. Shuster, K.D. O'Day, B. Penhallow, C.Y. Hung, A.M. Doweyko, A. Kamath, H. Zhang, P. Marathe, S.B. Kanner, T.A. Lin, J.H. Dodd, J.C. Barrish, and J. Wityak, Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorg. Med. Chem. Lett. 16 (2006), pp. 3706-3712.
19. R.J. Snow, A. Abeywardane, S. Campbell, J. Lord, M.A. Kashem, H.H. Khine, J. King, J.A. Kowalski, S.S. Pullen, T. Roma, G.P. Roth, C.R. Sarko, N.S. Wilson, M.P. Winters, J.P. Wolak, and C.L. Cywin, Hit-to-lead studies on benzimidazole inhibitors of ITK: Discovery of a novel class of kinase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 3660-3665.
20. K.J. Moriarty, H. Takahashi, S.S. Pullen, H.H. Khine, R.H. Sallati, E.L. Raymond, J.R. Woska Jr, D.D. Jeanfavre, G.P. Roth, M.P. Winters, L. Qiao, D. Ryan, R. DesJarlais, D. Robinson, M. Wilson, M. Bobko, B.N. Cook, H.Y. Lo, P.A. Nemoto, M.A. Kashem, J.P. Wolak, A. White, R.L. Magolda, and B. Tomczuk, Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk), Bioorg. Med. Chem. Lett. 18 (2008), pp. 5545-5549.
21. K.J. Moriarty, M. Winters, L. Qiao, D. Ryan, R. DesJarlis, D. Robinson, B.N. Cook, M.A. Kashem, P.V. Kaplita, L.H. Liu, T.M. Farrell, H.H. Khine, J. King, S.S. Pullen, G.P. Roth, R. Magolda, and H. Takahashi, Itk kinase inhibitors: Initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead, Bioorg. Med. Chem. Lett. 18 (2008), pp. 5537-5540.
22. M.P. Winters, D.J. Robinson, H.H. Khine, S.S. Pullen, J.R. Woska Jr, E.L. Raymond, R. Sellati, C.L. Cywin, R.J. Snow, M.A. Kashem, J.P. Wolak, J. King, P.V. Kaplita, L.H. Liu, T.M. Farrell, R. DesJarlais, G.P. Roth, H. Takahashi, and K.J. Moriarty, 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk), Bioorg. Med. Chem. Lett. 18 (2008), pp. 5541-5544.
23. B.N. Cook, J. Bentzien, A. White, P.A. Nemoto, J. Wang, C.C. Man, F. Soleymanzadeh, H.H. Khine, M.A. Kashem, S.Z. Kugler Jr, J.P. Wolak, G.P. Roth, S.D. Lombaert, S.S. Pullen, and H. Takahashi, Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design, Bioorg. Med. Chem. Lett. 19 (2009), pp. 773-777.
24. H.Y. Lo, J. Bentzien, R.W. Fleck, S.S. Pullen, H.H. Khine, J.R. Woska Jr, S.Z. Kugler, M.A. Kashem, and H. Takahashi, 2-Aminobenzimidazoles as potent ITK antagonists: Trans-stilbene-like moieties targeting the kinase specificity pocket, Bioorg. Med. Chem. Lett. 18 (2008), pp. 6218-6221.
25. D. Riether, R. Zindell, J.A. Kowalski, B.N. Cook, J. Bentzien, S.D. Lombaert, D. Thomson, S.Z. Kugler Jr, D. Skow, L.S. Martin, E.L. Raymond, H.H. Khine, K. O'Shea, J.R. Woska Jr, D. Jeanfavre, R. Sellati, K.L.M. Ralph, J. Ahlberg, G. Labissiere, M.A. Kashem, S.S. Pullen, and H. Takahashi, 5-Aminomethylbenzimdazoles as potent ITK antagonists, Bioorg. Med. Chem. Lett. 19 (2009), pp. 1588-1591.
26. H.Y. Lo, J. Bentzien, A. White, C.C. Man, R.W. Fleck, S.S. Pullen, H.H. Khine, J. King, J.R. Woska Jr, J.P. Wolak, M.A. Kashem, G.P. Roth, and H. Takahashi, 2-Aminobenzimidazoles as potent ITK antagonists: De novo design of a pyrrole system targeting additional hydrogen bonding interaction, Tetrahedron Lett. 49 (2008), pp. 7337-7340.
27. C.Y. Chen, Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping, J. Taiwan Inst. Chem. Eng. 40 (2009), pp. 155-161.
28. A. Smellie, S. Teig, and P. Towbin, Poling: Promoting conformational coverage, J. Comput. Chem. 16 (1995), pp. 171-187.
29. O.F. Guner, Pharmacophore Perception, Development, and Use in Drug Design, International University Line, La Jolla, California, 2000, pp. 173-188.
30. A.K. Debnath, Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of mycobacterium avium complex dihydrofolate reductase, J. Med. Chem. 45 (2002), pp. 41-53.
31. I.J. Macdougall and R. Griffith, Pharmacophore design and database searching for selective monoamine neurotransmitter transporter ligands, J. Mol. Graph. Model. 26 (2008), pp. 1113-1124.
32. N. Bharatham, K. Bharatham, and K.W. Lee, Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors, J. Mol. Graph. Model. 25 (2007), pp. 813-823.
33. K. Brown, J.M. Long, S.C. Vial, N. Dedi, N.J. Dunster, S.B. Renwick, A.J. Tanner, J.D. Frantz, M.A. Fleming, and G.M. Cheetham., Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitor, J. Biol. Chem. 279 (2004), pp. 18727-18732.
34. H.F. Li, T. Lu, T. Zhu, Y.J. Jiang, S.S. Rao, L.Y. Hu, B.T. Xin, and Y.D. Chen, Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas, Eur. J. Med. Chem. 44 (2009), pp. 1240-1249.